ocriplasmin Injectable Solution

Brand(s)
Jetrea
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Thrombogenics Inc. (2015-09-16)
Oldest Current Product
2012-10-31
License(s)
BLA
RxNORM
INJECTABLE SOLUTION\OCRIPLASMIN
SPL Active
INTRAVITREAL\INJECTION, SOLUTION\OCRIPLASMIN
SPL Moiety
INTRAVITREAL\INJECTION, SOLUTION\OCRIPLASMIN

product(s) by strength(s)

ocriplasmin 2.5 mg/ml injectable solution

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1248560001JetreaBLAThrombogenics Inc.2012-10-31OCRIPLASMININTRAVITREALINJECTION, SOLUTION125422390682b7-72c4-11e1-b0c4-0800200c9a66

application(s)

#idtitleapprovedtradenamesfda division
1125422ocriplasmin Application2012-10-17JetreaCDER

spl(s)

#idtitlecategorytypelabelerlabeler actlast updateversionproduct(s)
1390682b7-72c4-11e1-b0c4-0800200c9a66 (view SPL)These highlights do not include all the information needed to use JETREA safely and effectively. See full prescribing information for JETREA JETREA (ocriplasmin) Intravitreal Injection, 2.5 mg/mL Initial U.S. Approval: 2012prescriptionHuman PrescriptionThrombogenics Inc.API MANUFACTURE, LABEL, MANUFACTURE, PACK2015-09-166248560001

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII